Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,206,883 papers from all fields of science
Search
Sign In
Create Free Account
ixazomib
Known as:
{(1R)-1-[(2,5-dichlorobenzamido)acetamido]-3-methylbutyl}boronic Acid
An active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
15 relations
Broader (4)
Antineoplastic Agents
Boron Compounds
Glycine
Protease Inhibitors
Narrower (3)
MLN 9708
MLN2238
ixazomib citrate
NCIt Antineoplastic Agent Terminology
Positive Regulation of Apoptosis
Proteasome Function Inhibition
Proteasome Inhibitors [MoA]
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018.
E. Terpos
,
I. Ntanasis-Stathopoulos
Clinical Lymphoma, Myeloma & Leukemia
2019
Corpus ID: 132331230
2018
2018
Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome.
B. Hasinoff
Archives of Biochemistry and Biophysics
2018
Corpus ID: 20084189
Review
2017
Review
2017
Novel Therapies in Light Chain Amyloidosis
P. Milani
,
G. Merlini
,
G. Palladini
Kidney International Reports
2017
Corpus ID: 44113237
2017
2017
Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors
H. Jouni
,
M. Aubry
,
+4 authors
J. Herrmann
American journal of hematology/oncology
2017
Corpus ID: 20665521
The introduction of bortezomib has revolutionized the treatment of multiple myeloma (MM) and significantly improved outcomes in…
Expand
2017
2017
Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
K. Patel
,
J. Shah
,
+9 authors
R. Orlowski
2017
Corpus ID: 80441347
Background: Maintenance lenalidomide (Len) use in the post autologous stem cell transplant (ASCT) setting has demonstrated a…
Expand
2017
2017
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma
Wei Liu
,
Juan Chen
,
+11 authors
L. Pham
OncoTarget
2017
Corpus ID: 46746653
Despite advances in deciphering the molecular pathogenesis of diffuse large B-cell lymphoma (DLBCL), patients with relapsed…
Expand
2016
2016
Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment
Hao-yu Li
,
Zhenghu Chen
,
+9 authors
Jianhua Yang
Scientific Reports
2016
Corpus ID: 15746594
Neuroblastoma (NB) is the most common extracranial malignant solid tumor seen in children and continues to lead to the death of…
Expand
Review
2016
Review
2016
Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents
N. Nathwani
,
J. Larsen
,
P. Kapoor
Current Hematologic Malignancy Reports
2016
Corpus ID: 22678080
Advances in therapy in multiple myeloma have resulted in significant improvements in patient outcomes; however, relapse remains…
Expand
2015
2015
Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome…
P. Voorhees
,
Flora Mulkey
,
+7 authors
P. Richardson
2015
Corpus ID: 57719952
BACKGROUND: Pomalidomide-dexamethasone (Pom-Dex) represents an important therapeutic advance for the treatment of patients with…
Expand
Review
2005
Review
2005
Stem cell transplantation in multiple myeloma
B. Björkstrand
Hematology
2005
Corpus ID: 30714320
Single autologous transplantation High-dose treatment (HDT) with autologous stem cell transplantation (ASCT) has been shown to…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE